Abstract

Pharmacogenomics: Precision Pharmacy in 503A Compounding

Author(s): Drummond Joseph, Bennet Daron, Allen Loyd V Jr

Issue: Mar/Apr 2018 - Volume 22, Number 2

Page(s): 95-107

Download in electronic PDF format for $75
  • Pharmacogenomics: Precision Pharmacy in 503A Compounding Page 1
  • Pharmacogenomics: Precision Pharmacy in 503A Compounding Page 2
  • Pharmacogenomics: Precision Pharmacy in 503A Compounding Page 3
  • Pharmacogenomics: Precision Pharmacy in 503A Compounding Page 4
  • Pharmacogenomics: Precision Pharmacy in 503A Compounding Page 5
  • Pharmacogenomics: Precision Pharmacy in 503A Compounding Page 6
  • Pharmacogenomics: Precision Pharmacy in 503A Compounding Page 7
  • Pharmacogenomics: Precision Pharmacy in 503A Compounding Page 8
  • Pharmacogenomics: Precision Pharmacy in 503A Compounding Page 9
  • Pharmacogenomics: Precision Pharmacy in 503A Compounding Page 10
  • Pharmacogenomics: Precision Pharmacy in 503A Compounding Page 11
  • Pharmacogenomics: Precision Pharmacy in 503A Compounding Page 12
  • Pharmacogenomics: Precision Pharmacy in 503A Compounding Page 13

Abstract

The first recorded mention of a pharmacogenomic response may be that of Pythagoras in 510 BC, when he noted that hemolytic anemia developed in some but not all people who ingested fava beans. The application of such accounts to pharmacotherapy was inevitable, and customized medications have been compounded since antiquity to treat the needs of individual patients. Today, advances in pharmacogenomic testing yield results that enable more effective targeted therapies sooner in the course of treatment, prevent drug-related adverse effects, save cost, and ensure a better therapeutic outcome. The value of such testing is now more widely accepted, even in the public domain. It is our opinion that third-party payors will realize, to an increasing degree, that this new technology will save them money and will pay for it. Because independent compounding pharmacists have trusted relationships with patients and are convenient to visit, they are well placed to offer certain types of pharmacogenomic tests to patients and prescribers. In this article, topics that we address include the difference between pharmacogenomics and pharmacogenetics; the use of pharmacogenomic testing in 503A compounding; the benefits of such tests for patients, prescribers, and compounders; and suggestions for marketing pharmacogenomics testing. Information about a course that introduces pharmacogenomic science to compounders is provided, and suggestions for additional reading and other resources about pharmacogenomic testing are included for easy reference.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2018
Pg. 95-107
Mar/Apr 2018
Pg. 108-121
Mar/Apr 2003
Pg. 106-113
Author(s): Davidson Gigi S
Sep/Oct 2017
Pg. 356
Author(s): Allen Loyd V Jr
Sep/Oct 2014
Pg. 379-380
Nov/Dec 2022
Pg. 474-479
Author(s): Maham Nicole Y
Jul/Aug 2015
Pg. 280-287
Author(s): Allen Loyd V
Jan/Feb 2020
Pg. 30-36
Author(s): Dillon L R
Jul/Aug 2016
Pg. 351
View Sample
Author(s): Allen Loyd V Jr
Mar/Apr 2017
Pg. 95-102
Author(s): Yoch Doug
May/Jun 2016
Pg. 202-206
Author(s): Newton David W
Nov/Dec 2011
Pg. 526-527
Author(s): Williams LaVonn A
Nov/Dec 2015
Pg. 487-488
Author(s): Allen Loyd V Jr
Sep/Oct 2021
Pg. 358-362
Author(s): Cabaleiro Joe
Nov/Dec 2012
Pg. 456-460
Author(s): Lyon Joanna
Mar/Apr 2022
Pg. 100-109
Author(s): Broughel James
Jul/Aug 2022
Pg. 298-301
Author(s): Ofei Kelvin
Jul/Aug 2012
Pg. 294-298
Sep/Oct 2014
Pg. 358-364
Mar/Apr 2011
Pg. 92
Author(s): Allen Loyd V Jr